Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Sunday 08 August 2021 7:30 am  |  Updated:  Sunday 08 August 2021 4:51 pm

NHS waiting list could top 13 million, says IFS

By: Lily Russell-Jones

Add as a preferred source on Google
NHS waiting list could double to 13 million
The NHS waiting list could reach 13 million unless capacity is expanded rapidly, says IFS

IFS modelling has confirmed Sajid Javid’s stark warning that the number of people on the NHS waiting list could reach 13 million.

Last month the Health and Social Care Secretary quoted “shocking” government data which estimated waiting lists could more than double in a matter of months. Today, analysis published by the IFS reiterated that more than 13 million patients may be awaiting treatment by July 2022.

The waiting list reached a record 5.3 million in May 2021, up from 4.4 million in February 2020. However, modelling suggests that this figure falls well below the true number of patients in need of medical care.

A shortfall of 7.4 million ‘missing’ patients was identified when comparing data from 2020 and 2021 with pre-pandemic patient patterns. It is thought that during lockdown many patients who should have come forwards to seek medical attention did not.

Waiting lists will rise exponentially unless the NHS expands capacity beyond pre-pandemic levels. According to the report even if the NHS achieves its current target of returning capacity to 95% of pre-pandemic levels waiting lists will exceed 13 million if just two thirds of the missing patients come forward.

Max Warner, a Research Economist at IFS and an author of the analysis, said: “There is a real risk that if the NHS cannot find effective ways to boost its capacity – a challenge at the best of times, let alone after a major pandemic – then much longer waiting lists will be with us for years to come.”

As of March 2021 436,000 people had been on the NHS waiting list for over a year, a 200-fold increase compared to pre-pandemic levels.

Read more: CMA accuses pharma firms Pfizer and Flynn of charging NHS illegal prices for anti-epilepsy drug

Read more

Semble Secures £30M Series C Investment Led by Revaia to Expand Europe’s Connected Healthcare Platform

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • NHS

Trending Articles

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Barclays and Lloyds join banking sector plan for digital ID

  • Clarkson’s Farm and why businesses must stop blaming the weather

More from City PM

  • Semble Secures £30M Series C Investment Led by Revaia to Expand Europe’s Connected Healthcare Platform

    Business Wire
  • Harley Street Health District Releases First Annual Impact Report

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy